Mylan is committed to supporting educational initiatives that facilitate health care provider education, advance the quality of patient care, and align with Mylan therapeutic and clinical interests.  Mylan will accept educational grant requests for the following professional medical education programs:
  • Accredited continuing medical education providers 
  • Hospitals, community health centers
  • Academic medical centers, medical universities
  • Professional medical associations/societies
  • Managed care organizations
  • Medical education partner companies/providers
Mylan is accepting applications for professional medical education programs through our online application system for the United States on Friday, March 1, 2019 through Monday, September 30, 2019.

Mylan is currently accepting U.S. medical education grants for the following areas: Asthma/COPD, Biosimilars, Cystic Fibrosis, and HIV/ARV.

For specific grant program priority topics for the United States, please see below.

Components of a Complete U.S. Grant Request Include – Letter of request/program description, agenda, program objectives, detailed budget, and (ACCME certificate for accredited programs)

United States 2019 Unrestricted Educational Grants Priority Topics

Asthma and COPD 
  • Nebulization therapy in COPD, including in acute care settings
  • Identification of at risk populations who might benefit from nebulized therapy (screening algorithm)
  • Variables that play a role in re-hospitalization and readmission (i.e. PIFR, devices mistakes, etc.)
  • Combination treatment strategy in COPD 
  • Generics in Respiratory 
  • Ability to improve adherence compliance with once-daily nebulized therapy
  • COPD treatment strategy for discharge after AECOPD to reduce re-hospitalization and 30-day readmission rates
  • Reducing Re-hospitalization after COPD exacerbation
  • Asthma-COPD overlap (ACO)
  • Annual Respiratory conferences: scientific programs and educational symposia
  • Pharmacology of biosimilars
  • Drug development
  • Evolution of pharmacologic therapy
  • Economic impact of biosimilars
  • Immunotherapy in oncology/rheumatology/endocrinology
Cystic Fibrosis
  • Antibiotic use on CF
  • CF updates in existing and future treatments and the impact in antibiotic therapy
  • CF outcomes
  • Antibiotic combination and new schemes of treatment
  • Resistance risk in patients with CF
  • Pseudomona aeruginosa eradication
  • Role of Novel ARV Guidelines/ Substitutable therapies
  • FDCs with reduced doses in HIV treatment
  • Role of new once daily combinations based on older compounds
  • Current and evolving HIV treatment strategy 
  • Annual HIV conferences: scientific programs
  • Budget Impact and economic repercussions of new ARVs